0001822462 2022-01-01 2022-03-31 0001822462 2022-04-29 shares true 2022 Q1 0001822462 --12-31 10-Q/A true 2022-03-31 false 001-39634 Foghorn Therapeutics Inc. DE 47-5271393 500 Technology Square, Ste 700 Cambridge MA 02139 617 586-3100 Common Stock, $0.0001 par value per share FHTX NASDAQ Yes Yes Non-accelerated Filer true true false false 41467808 EXPLANATORY NOTEFoghorn Therapeutics Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) on Form 10-Q/A to amend its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Securities and Exchange Commission on May 9, 2022 (the “Original 10-Q”), for the purpose of filing revised versions of Exhibits 31.1 and 31.2 filed with the Original 10-Q.The Company is filing revised exhibits solely in order to include in the certifications set forth in the Exhibits the language added to the introductory portion of paragraph 4 and the language of revised paragraph 4(b), which language was inadvertently omitted from the certifications when originally filed. This Amendment does not reflect events occurring after the date of the filing of the Original 10-Q or modify or update any of the other disclosures contained therein in any way. Accordingly, this Amendment should be read in conjunction with the Original 10-Q. This Amendment consists solely of the preceding cover page, this Explanatory Note, the signature page and paragraphs 1, 2, 4 and 5 of each of the revised certifications filed as exhibits to the Amendment. Because no financial statements have been include in this Amendment, paragraph 3 of each of the certifications set forth in the Exhibits has been omitted.